Given the growing number of patients suffering from cardiovascular disorders and the high associated financial burden, cardiovascular drug eluting stents have emerged as a safe and efficient novel drug delivery device to assist in providing effectual treatment.
Roots Analysis has announced the addition of “Novel Cardiovascular Drug Delivery Devices Market, 2022-2035” report to its list of offerings.
In order to prevent the critical effects of vessel narrowing and plaque buildup in arteries, various coronary interventional devices are being used; cardiovascular stents have emerged as one of the most preferred solutions to mitigate the aforementioned concerns. Traditionally, bare-metal stents were used extensively to open the blocked passages and restore adequate blood flow to the heart. However, in recent years, a shift in preference has been observed towards the use of drug-eluting stents, which are coated with a polymer carrying an antiproliferative drug.
Key Market Insights
Over 90 cardiovascular drug eluting stents are presently available in this market space
About 65% of these devices are coated with sirolimus drug, followed by those coated with everolimus and paclitaxel. Further, more than 70% of the stents are manufactured by using cobalt alloy. It is interesting to mention that stent length of more than 85% of the devices is in the range of 31 mm to 50 mm.
~40 players are currently be engaged in the production of cardiovascular drug eluting stents
Majority of the players engaged in this domain are large firms (501-10,000 employees, 41%), followed by mid-sized players (51-500 employees, 26%), very large players (10,000+ employees, 18%) and small (2-50 employees, 15%) companies. Additionally, most of the service providers (38%) are based in Asia, followed by those having headquarters in Europe and North America.
For additional details, please visit https://www.rootsanalysis.com/reports/novel-cardiovascular-drug-delivery-devices-market.html or email [email protected]